DECEMBER 2022LIFE SCIENCES REVIEW8IN MY OPINIONWORLDWIDE PATIENTS' ACCESS TO LIFE-CHANGING THERAPIESBy Kinga Bercsenyi, PhD, European Lead for Precision Medicine & Biomarker Solutions, Cerba ResearchI'm curious about the market's present state from your viewpoint given the level of experience you've gained over the years. What do you think are some of the most pressing issues currently?Patient recruitment for studies has been extremely difficult due to COVID and the global pandemic. Decentralized studies have been encouraged by it, so patients are no longer required to attend all of their visits in the clinic. It's fascinating to see how they're attempting to shift healthcare towards a more at-home and portable model. And in parallel with this, we also had a huge evolution in technology. When you consider the human genome's sequencing, it cost millions of dollars and ten years to complete a single sequence. Nowadays, we can do it for $1,000 in essentially one day, which is amazing. Another challenge in precision medicine is to effectively synchronise the high throughput data that we are currently obtaining, understand how to best position artificial intelligence, while also still maintaining some level of human control over it so that we get meaningful results and real-world evidence. There are many obstacles, but there is the technology and will to overcome them.What have been the most recent changes or trends in the market, in your opinion?In immuno-oncology, we are nearing a point where we can truly identify individuals who would benefit from certain With an expertise in R&D, project management, and business development, Kinga Bercsenyi is a life science expert with a special focus on oncology and immuno-oncology. Her dual role as a scientist and business development consultant requires her to establish strategic partnerships with top pharmaceutical companies and focus on gathering as much meaningful information as she can about research, support, and the capacity to plan clinical trials to help with the development of patient-specific medications. Kinga Bercsenyi
< Page 7 | Page 9 >